Evidence map›Paper›PMID 32450807›Full record

ArticleBMC immunology2020

Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.

Tew Hui Xian, Kurunathan Sinniah, Chan Yean Yean, Venkateskumar Krishnamoorthy, Mohd Baidi Bahari, Manickam Ravichandran, Guruswamy Prabhakaran

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Bacterial Ghosts ofVaccines · 2022
    Article
  4. Article
  5. Correlates of Protection for Cholera.The Journal of infectious diseases · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tew Hui XianDepartment of Biotechnology, Faculty of Applied Sciences, AIMST University, 08100, Semeling, Kedah, Malaysia.
Kurunathan SinniahDepartment of Biotechnology, Faculty of Applied Sciences, AIMST University, 08100, Semeling, Kedah, Malaysia.
Chan Yean YeanDepartment of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia.
Venkateskumar KrishnamoorthyFaculty of Pharmacy, AIMST University, 08100, Semeling, Kedah, Malaysia.
Mohd Baidi BahariFaculty of Pharmacy, AIMST University, 08100, Semeling, Kedah, Malaysia.
Manickam RavichandranCentre of Excellence for Omics-Driven Computational Biodiscovery, Faculty of Applied Sciences, AIMST University, 08100, Semeling, Kedah, Malaysia.
Guruswamy PrabhakaranDepartment of Biotechnology, Faculty of Applied Sciences, AIMST University, 08100, Semeling, Kedah, Malaysia. guruswamy.prabhakaran@gmail.com.ORCID 0000-0002-5092-3941
AIMST University · MYUniversiti Sains Malaysia · MY

Funding

Prototype Development Research Grant Scheme PRGS/2/2015/ SKK10/AIMST/02/1
6 · The paper itself

Abstract

backgroundCholera, an acute watery diarrhoeal disease caused by Vibrio cholerae serogroup O1 and O139 across the continents. Replacing the existing WHO licensed killed multiple-dose oral cholera vaccines that demand 'cold chain supply' at 2-8 °C with a live, single-dose and cold chain-free vaccine would relieve the significant bottlenecks and cost determinants in cholera vaccination campaigns. In this direction, a prototype cold chain-free live attenuated cholera vaccine formulation (LACV) was developed against the toxigenic wild-type (WT) V. cholerae O139 serogroup. LACV was found stable and retained its viability (5 × 10

resultsThe LACV was evaluated for its colonization potential, reactogenicity, immunogenicity and protective efficacy in animal models after its storage at room temperature for 140 days. In suckling mice colonization assay, the LACV recorded the highest recovery of (7.2 × 10

conclusionThe vaccine formulation mimics a natural infection, is non-reactogenic and highly immunogenic in vivo and protects animals from lethal wild-type V. cholerae O139 challenge. The single dose LACV formulation was found to be stable at room temperature (25 ± 2 °C) for 140 days and it would result in significant cost savings during mass cholera vaccination campaigns.

Indexed as

Administration, OralAnimalsAntibodies, BacterialAntibody FormationCholeraCholera VaccinesMaleMiceMice, Inbred BALB CRabbitsRefrigerationVaccinationVaccines, AttenuatedVibrio choleraeAntibodies, BacterialCholera VaccinesVaccines, AttenuatedLive attenuatedRabbit ileal loopReactogenicityRITARDThermostable vaccineVibrio cholerae O139

Identifiers

PMID32450807
PMCPMC7249306
OpenAlexW3032583977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.